

Chapter 8

References

References

1. Gluz, O., et al., *Triple-negative breast cancer--current status and future directions*. Ann Oncol, 2009. **20**(12): p. 1913-1927.
2. Podo, F., et al., *Triple-negative breast cancer: present challenges and new perspectives*. Mol Oncol, 2010. **4**(3): p. 209-229.
3. Boyle, P., *Triple-negative breast cancer: epidemiological considerations and recommendations*. Ann Oncol, 2012. **23** (6): p. vi7-vi12.
4. Sandhu, G.S., et al., *Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis*. J Glob Oncol., 2016. **2**(6): p. 412-421.
5. Abramson, V.G. and I.A. Mayer, *Molecular Heterogeneity of Triple Negative Breast Cancer*. Curr Breast Cancer Rep, 2014. **6**(3): p. 154-158.
6. Uscanga-Perales, G.I., S.K. Santuario-Facio, and R. Ortiz-López, *Triple negative breast cancer: Deciphering the biology and heterogeneity*. Medicina Universitaria, 2016. **18**(71): p. 105-114.
7. Bianchini, G., et al., *Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease*. Nat Rev Clin Oncol, 2016. **13**(11): p. 674-690.
8. Turkman, Y.E., et al., *Biologic, demographic, and social factors affecting triple negative breast cancer outcomes*. Clin J Oncol Nurs, 2015. **19**(1): p. 62-67.
9. Al-Mahmood, S., et al., *Metastatic and triple-negative breast cancer: challenges and treatment options*. Drug Deliv Transl Res, 2018. **8**(5): p. 1483-1507.
10. De Craene, B. and G. Berx, *Regulatory networks defining EMT during cancer initiation and progression*. Nat Rev Cancer, 2013. **13**(2): p. 97-110.
11. Ferrari-Amorotti, G., et al., *Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity*. Neoplasia, 2014. **16**(12): p. 1047-1058.
12. Choi SK, et al., *LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer*. Oncotarget, 2017. **8**(7): p. 11977-11989.
13. Neophytou, C., P. Boutsikos, and P. Papageorgis, *Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis*. Frontiers in Oncology, 2018. **8**(31): p. 1-13.
14. Firatligil-Yildirim, B., O. Yalcin-Ozuysal, and Nonappa, *Recent advances in lab-on-a-chip systems for breast cancer metastasis research*. Nanoscale Advances, 2023. **5**(9): p. 2375-2393.
15. Obidiro, O., G. Battogtokh, and E.O. Akala, *Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook*. Pharmaceutics, 2023. **15**(7): p. 1-26.
16. Li, S., et al., *Feasibility of Eradication of Breast Cancer Cells Remaining in Postlumpectomy Cavity and Draining Lymph Nodes following Intracavitary Injection of Radioactive Immunoliposomes*. Molecular Pharmaceutics, 2012. **9**(9): p. 2513-2522.

17. Yao, Y., et al., *Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer*. *Cancer Med*, 2019. **8**(2): p. 554-563.
18. Yin, L., et al., *Triple-negative breast cancer molecular subtyping and treatment progress*. *Breast Cancer Res*, 2020. **22**(61): p. 1-13.
19. Connolly, E. *Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer With and Without Intra-operative RT: a Window of Opportunity Study*. 2017 [Accessed on 14-10-2024].
20. Furlanetto, J. and S. Loibl, *Optimal Systemic Treatment for Early Triple-Negative Breast Cancer*. *Breast Care*, 2020. **15**(3): p. 217-226.
21. Gupta, G.K., et al., *Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies*. *Cancers (Basel)*, 2020. **12**(2392): p. 1-33.
22. Vaz-Luis, I., et al., *Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study*. *J Clin Oncol*, 2014. **32**(20): p. 2142-2150.
23. Nunez Abad, M., et al., *Update on systemic treatment in early triple negative breast cancer*. *Ther Adv Med Oncol*, 2021. **13**: p. 1-18.
24. Yadav, B.S., *Systemic treatment strategies for triple-negative breast cancer*. *World Journal of Clinical Oncology*, 2014. **5**(2): p. 125-133.
25. Keenan, T.E. and S.M. Tolaney, *Role of Immunotherapy in Triple-Negative Breast Cancer*. *Journal of the National Comprehensive Cancer Network*, 2020. **18**(4): p. 479-489.
26. O'Reilly, D., M.A. Sendi, and C.M. Kelly, *Overview of recent advances in metastatic triple negative breast cancer*. *World J Clin Oncol*, 2021. **12**(3): p. 164-182.
27. Mustacchi, G. and M. De Laurentiis, *The role of taxanes in triple-negative breast cancer: literature review*. *Drug Des Devel Ther*, 2015. **9**: p. 4303-4318.
28. Polkinghorn, W.R. and N.J. Tarbell, *Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification*. *Nat Clin Pract Oncol*, 2007. **4**(5): p. 295-304.
29. Clarke, R.B., et al., *A putative human breast stem cell population is enriched for steroid receptor-positive cells*. *Dev Biol*, 2005. **277**(2): p. 443-456.
30. Soffietti, R., E. Trevisan, and R. Ruda, *Neurologic complications of chemotherapy and other newer and experimental approaches*. *Handb Clin Neurol*, 2014. **121**: p. 1199-218.
31. Ahmed, F.S., et al., *PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer*. *Clin Cancer Res*, 2020. **26**(20): p. 5456-5461.
32. Hargadon, K.M., C.E. Johnson, and C.J. Williams, *Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors*. *Int Immunopharmacol*, 2018. **62**: p. 29-39.

33. Brautigam, K., et al., *Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines*. J Cancer Res Clin Oncol, 2021. **147**(10): p. 2923-2933.
34. Peng, Z., et al., *Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis*. J Cancer, 2020. **11**(21): p. 6365-6375.
35. Zhu, Y., et al., *Progress and challenges of immunotherapy in triple-negative breast cancer*. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021. **1876**(2): p. 1-14.
36. Luo, C., et al., *Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer*. Front Oncol, 2022. **12**: p. 1-22.
37. Rottenberg S, et al., *High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs*. Proc Natl Acad Sci U S A., 2008. **105**(44): p. 17079-17084.
38. Dai, M., et al., *CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer*. Scientific Reports, 2016. **6**(35383): p. 1-15.
39. Kalimutho, M., et al., *Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease*. Trends in Pharmacological Sciences, 2015. **36**(12): p. 822-846.
40. Turner, N., et al., *Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets*. Oncogene, 2010. **29**(14): p. 2013-2023.
41. Crown, J., J. O'Shaughnessy, and G. Gullo, *Emerging targeted therapies in triple-negative breast cancer*. Ann Oncol, 2012. **23** (6): p. vi56-vi65.
42. Saal LH, et al., *PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma*. Cancer Res. , 2005. **65**(7): p. 2554-2559.
43. Khan, M., et al., *PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges*. Drug Discov Today., 2019. **24**(11): p. 2181-2191.
44. Barton, V.N., et al., *Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo*. Mol Cancer Ther, 2015. **14**(3): p. 769-778.
45. Cochrane DR, et al., *Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide*. Breast Cancer Res., 2014. **16**(1): p. 1-19.
46. Lehmann, B.D., et al., *Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies*. J Clin Invest, 2011. **121**(7): p. 2750-2767.
47. Shin, E., Y. Lee, and J.S. Koo, *Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology*. Journal of Translational Medicine, 2016. **14**(87): p. 1-11.
48. Muvarak, N.E., et al., *Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer*. Cancer Cell, 2016. **30**(4): p. 637-650.

49. Chaudhuri, A., et al., *Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)*. Pharmaceuticals (Basel), 2022. **15**(5): p. 1-63.
50. Mudshinge, S.R., et al., *Nanoparticles: Emerging carriers for drug delivery*. Saudi Pharm J, 2011. **19**(3): p. 129-141.
51. Dhankhar, R., et al., *Advances in novel drug delivery strategies for breast cancer therapy*. Artif Cells Blood Substit Immobil Biotechnol, 2010. **38**(5): p. 230-249.
52. Pawar, H., et al., *Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: In vitro evaluation, pharmacokinetic and biodistribution in rats*. Drug Deliv, 2016. **23**(4): p. 1453-1468.
53. Lensen, D., et al., *Biodegradable polymeric microcapsules for selective ultrasound-triggered drug release*. Soft Matter, 2011. **7**(5417): p. 1-6.
54. Meng, H., et al., *Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo*. ACS Nano, 2013. **7**(2): p. 994-1005.
55. VP, T., *Recent advances with liposomes as pharmaceutical carriers*. Nat Rev Drug Discov., 2005. **4**(2): p. 145-160.
56. Barenholz, Y., *Doxil(R)-the first FDA-approved nano-drug: lessons learned*. J Control Release, 2012. **160**(2): p. 117-134.
57. Gu, J., et al., *Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery*. Biomaterials, 2015. **45**: p. 99-114.
58. Miller, A.D., *Lipid-based nanoparticles in cancer diagnosis and therapy*. J Drug Deliv, 2013. **2013**: p. 1-9.
59. Liu, Y., et al., *Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor*. Nat Commun, 2015. **6**(5988): p. 1-18.
60. Ha, D., N. Yang, and V. Nadithe, *Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges*. Acta Pharm Sin B, 2016. **6**(4): p. 287-296.
61. Mao, L., et al., *Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs*. Tumour Biol, 2016. **37**(4): p. 5247-5256.
62. Attia MF, et al., *An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites*. J Pharm Pharmacol. , 2019. **71**(8): p. 1185-1198.
63. Kobayashi, H., R. Watanabe, and P.L. Choyke, *Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?* Theranostics, 2014. **4**(1): p. 81-89.
64. Wang, X., et al., *The development of site-specific drug delivery nanocarriers based on receptor mediation*. J Control Release, 2014. **193**: p. 139-153.
65. Otvos, L., Jr., et al., *Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer*. Eur J Cancer, 2011. **47**(10): p. 1578-1584.

66. Lipsey, C.C., et al., *Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer*. Int J Mol Sci, 2020. **21**(11): p. 1-21.
67. Taftaf, R., et al., *ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer*. Nat Commun, 2021. **12**(4867): p. 1-15.
68. DeCarlo, A., C. Malardier-Jugroot, and M. R Szewczuk, *Folic Acid Conjugated Copolymer and Folate Receptor Interactions Disrupt Receptor Functionality Resulting in Dual Therapeutic AntiCancer Potential in Triple-Negative Breast Cancer*. Preprints 2020. **32**(3): p. 512-522.
69. Koni, M., et al., *Interleukin-3-Receptor-alpha in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target*. Cancers (Basel), 2022. **14**(3918): p. 1-18.
70. Malavia, N., et al., *A bird's eye view of the advanced approaches and strategies for overshadowing triple negative breast cancer*. J Control Release, 2021. **330**: p. 72-100.
71. Chaudhari, R., V. Patel, and A. Kumar, *Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies*. Nanoscale Adv, 2024. **6**(9): p. 2270-2286.
72. Chalakur-Ramireddy, N.K.R. and S.B. Pakala, *Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer*. Biosci Rep, 2018. **38**(1): p. 1-14.
73. Herbst, R.S. and F.R. Khuri, *Mode of action of docetaxel - a basis for combination with novel anticancer agents*. Cancer Treat Rev, 2003. **29**(5): p. 407-415.
74. Anand, U., et al., *Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics*. Genes Dis, 2023. **10**(4): p. 1367-1401.
75. Gerdes, M.J., et al., *Emerging understanding of multiscale tumor heterogeneity*. Front Oncol, 2014. **4**(366): p. 1-12.
76. Sporikova, Z., et al., *Genetic Markers in Triple-Negative Breast Cancer*. Clin Breast Cancer, 2018. **18**(5): p. e841-e850.
77. Dowell, J., J.D. Minna, and P. Kirkpatrick, *Erlotinib hydrochloride*. Nature Reviews Drug Discovery, 2005. **4**(1): p. 13-14.
78. Ali Khan, A., et al., *Advanced drug delivery to the lymphatic system: lipid-based nanoformulations*. Int J Nanomedicine, 2013. **8**: p. 2733-2744.
79. Goke, K. and H. Bunjes, *Drug solubility in lipid nanocarriers: Influence of lipid matrix and available interfacial area*. Int J Pharm, 2017. **529**(1-2): p. 617-628.
80. Beloqui, A., et al., *Nanostructured lipid carriers: Promising drug delivery systems for future clinics*. Nanomedicine, 2016. **12**(1): p. 143-161.
81. Chauhan, I., et al., *Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery*. Adv Pharm Bull, 2020. **10**(2): p. 150-165.
82. Chaudhuri, A., et al., *Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy*. Int J Mol Sci, 2022. **23**(17): p. 1-39.

83. Hallan, S.S., et al., *Challenges in the Physical Characterization of Lipid Nanoparticles*. Pharmaceutics, 2021. **13**(549): p. 1-31.
84. Parvez, S., et al., *Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis*. Sci Rep, 2020. **10**(12243): p. 1-14.
85. Edis, Z., et al., *Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives*. Int J Nanomedicine, 2021. **16**: p. 1313-1330.
86. Talluri, S.V., et al., *Lipid-based nanocarriers for breast cancer treatment - comprehensive review*. Drug Deliv, 2016. **23**(4): p. 1291-1305.
87. Cheng, Z., et al., *Nanomaterials for cancer therapy: current progress and perspectives*. J Hematol Oncol, 2021. **14**(85): p. 1-27.
88. Puri A, et al., *Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic*. Crit Rev Ther Drug Carrier Syst, 2009. **26**(6): p. 523-580.
89. Clemons, T.D., et al., *Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy*. Langmuir, 2018. **34**(50): p. 15343-15349.
90. Song, D.G., et al., *Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level*. J Hematol Oncol, 2016. **9**(56): p. 1-12.
91. Cheung A, et al., *Targeting folate receptor alpha for cancer treatment*. Oncotarget, , 2016. **7**(32): p. 52553-52574.
92. da Rocha, M.C.O., et al., *Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells*. J Nanobiotechnology, 2020. **18**(43): p. 1-20.
93. Chaowanachan, T., et al., *Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis*. PLoS One, 2013. **8**(4): p. 1-13.
94. Sakellari, G.I., et al., *Formulation design, production and characterisation of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the encapsulation of a model hydrophobic active*. Food Hydrocoll Health, 2021. **1**: p. 1-18.
95. Iqbal, B., J. Ali, and S. Baboota, *Silymarin loaded nanostructured lipid carrier: From design and dermatokinetic study to mechanistic analysis of epidermal drug deposition enhancement*. Journal of Molecular Liquids, 2018. **255**: p. 513-529.
96. Managuli, R.S., et al., *Asenapine maleate-loaded nanostructured lipid carriers: optimization and in vitro, ex vivo and in vivo evaluations*. Nanomedicine, 2019. **14**(7): p. 889-910.
97. Akhoond Zardini, A., et al., *Production and characterization of nanostructured lipid carriers and solid lipid nanoparticles containing lycopene for food fortification*. J Food Sci Technol, 2018. **55**(1): p. 287-298.
98. Venishetty, V.K., et al., *Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles*. Nanomedicine, 2013. **9**(1): p. 111-121.

99. Suriamoorthy, P., et al., *Folic acid-CdTe quantum dot conjugates and their applications for cancer cell targeting*. Cancer Nanotechnol, 2010. **1**(1-6): p. 19-28.
100. Kumar, D.N., et al., *Combination therapy comprising paclitaxel and 5-fluorouracil by using folic acid functionalized bovine milk exosomes improves the therapeutic efficacy against breast cancer*. 2022. **12**(8): p. 1-20.
101. Agrawal, A.K., et al., *Folate appended chitosan nanoparticles augment the stability, bioavailability and efficacy of insulin in diabetic rats following oral administration*. RSC Advances, 2015. **5**(127): p. 105179-105193.
102. Pereira, R.R., et al., *Ucuuba (Virola surinamensis) Fat-Based Nanostructured Lipid Carriers for Nail Drug Delivery of Ketoconazole: Development and Optimization Using Box-Behnken Design*. Pharmaceutics, 2019. **11**(284): p. 1-25.
103. Agrawal, A.K., et al., *Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration*. 2014. **15**(1): p. 350-360.
104. Shete, H. and V. Patravale, *Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization*. Int J Pharm, 2013. **454**(1): p. 573-583.
105. Harde, H., A.K. Agrawal, and S. Jain, *Tetanus toxoid-loaded layer-by-layer nanoassemblies for efficient systemic, mucosal, and cellular immunostimulatory response following oral administration*. Drug Deliv Transl Res, 2015. **5**(5): p. 498-510.
106. Cunha, S., et al., *Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters*. Pharmaceutics, 2020. **12**(599): p. 1-25.
107. Wijaya, W., et al., *Improved bioaccessibility of polymethoxyflavones loaded into high internal phase emulsions stabilized by biopolymeric complexes: A dynamic digestion study via TNO's gastrointestinal model*. Curr Res Food Sci, 2020. **2**: p. 11-19.
108. Ibrahim, W.N., L. Muizzuddin Bin Mohd Rosli, and A.A. Doolaanea, *Formulation, Cellular Uptake and Cytotoxicity of Thymoquinone-Loaded PLGA Nanoparticles in Malignant Melanoma Cancer Cells*. Int J Nanomedicine, 2020. **15**: p. 8059-8074.
109. Abdi Goushbolagh, N., et al., *Quantitative Cytotoxicity, Cellular Uptake and Radioprotection Effect of Cerium Oxide Nanoparticles in MRC-5 Normal Cells and MCF-7 Cancerous Cells*. BioNanoScience, 2018. **8**(3): p. 769-777.
110. Niazvand, F., et al., *Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells*. Medicina (Kaunas), 2019. **55**(114): p. 1-15.
111. Nordin, N., et al., *In vitro cytotoxicity and anticancer effects of citral nanostructured lipid carrier on MDA MBA-231 human breast cancer cells*. Sci Rep, 2019. **9**(1614): p. 1-19.
112. Yu, K.N., et al., *Zinc oxide nanoparticle induced autophagic cell death and mitochondrial damage via reactive oxygen species generation*. Toxicol In Vitro, 2013. **27**(4): p. 1187-1195.

113. Paget, V., et al., *Human Cell Line-Dependent WC-Co Nanoparticle Cytotoxicity and Genotoxicity: A Key Role of ROS Production*. Toxicological Sciences, 2015. **143**(2): p. 385-397.
114. Haque, S., et al., *Biosynthesized Silver Nanoparticles for Cancer Therapy and In Vivo Bioimaging*. Cancers (Basel), 2021. **13**(23): p. 1-26.
115. Deng, G., et al., *Inhibition of cancer cell migration with CuS@ mSiO(2)-PEG nanoparticles by repressing MMP-2/MMP-9 expression*. Int J Nanomedicine, 2018. **13**: p. 103-116.
116. Chaurawal, N., et al., *Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies*. Sci Rep, 2022. **12**(1): p. 1-15.
117. Pooja, D., et al., *Improving Efficacy, Oral Bioavailability, and Delivery of Paclitaxel Using Protein-Grafted Solid Lipid Nanoparticles*. Mol Pharm, 2016. **13**(11): p. 3903-3912.
118. Mirzaghavami, P.S., et al., *Folic acid-conjugated magnetic triblock copolymer nanoparticles for dual targeted delivery of 5-fluorouracil to colon cancer cells*. Cancer Nanotechnology, 2022. **13**(12): p. 1-18.
119. Fu, Q.T., et al., *Luteolin-Loaded Nanoparticles for the Treatment of Melanoma*. Int J Nanomedicine, 2023. **18**: p. 2053-2068.
120. Sethuraman, V., et al., *In vivo synergistic anti-tumor effect of lumefantrine combined with pH responsive behavior of nano calcium phosphate based lipid nanoparticles on lung cancer*. Eur J Pharm Sci, 2021. **158**(105657): p. 1-10.
121. Meena, D., K. Vimala, and S. Kannan, *Combined Delivery of DOX and Kaempferol using PEGylated Gold Nanoparticles to Target Colon Cancer*. Journal of Cluster Science, 2021. **33**(1): p. 173-187.
122. Harish, V., et al., *Quality by Design Based Formulation of Xanthohumol Loaded Solid Lipid Nanoparticles with Improved Bioavailability and Anticancer Effect against PC-3 Cells*. Pharmaceutics, 2022. **14**(2403): p. 1-27.
123. Bose, S., et al., *Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems*. Int J Pharm, 2013. **441**(2): p. 56-66.
124. Zhang, R.X., et al., *Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives*. J Control Release, 2016. **240**: p. 489-503.
125. Chen, C., et al., *Ratiometric co-delivery of multiple chemodrugs in a single nanocarrier*. Eur J Pharm Sci, 2017. **107**: p. 16-23.
126. Badawi, N., et al., *Development of Pomegranate Extract-Loaded Solid Lipid Nanoparticles: Quality by Design Approach to Screen the Variables Affecting the Quality Attributes and Characterization*. ACS Omega, 2020. **5**(34): p. 21712-21721.
127. Banerjee, S., et al., *Comparative study of oral lipid nanoparticle formulations (LNFs) for chemical stabilization of antitubercular drugs: physicochemical and cellular evaluation*. Artif Cells Nanomed Biotechnol, 2018. **46**(sup1): p. 540-558.
128. Wang, Y., et al., *Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles*. Drug Deliv, 2015. **22**(2): p. 191-198.

129. De, A., et al., *Folic Acid Functionalized Diallyl Trisulfide-Solid Lipid Nanoparticles for Targeting Triple Negative Breast Cancer*. *Molecules*, 2023. **28**(3): p. 1-17.
130. Almalik, A., et al., *Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating*. *Saudi Pharm J*, 2017. **25**(6): p. 861-867.
131. Nguyen, T.-T.-L. and V.-A. Duong, *Solid Lipid Nanoparticles*. *Encyclopedia*, 2022. **2**(2): p. 952-973.
132. Thiruchenthooran, V., et al., *Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers*. *Int J Mol Sci*, 2022. **23**(19): p. 1-18.
133. Velmurugan, R. and S. Selvamuthukumar, *Development and optimization of ifosfamide nanostructured lipid carriers for oral delivery using response surface methodology*. *Applied Nanoscience*, 2015. **6**(2): p. 159-173.
134. Elmowafy, M., et al., *Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks*. *Drug Deliv*, 2017. **24**(1): p. 932-941.
135. Sahrayi, H., et al., *Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression*. *Pharmaceuticals (Basel)*, 2021. **15**(6): p. 1-19.
136. Aditya, N.P., et al., *Development and evaluation of lipid nanocarriers for quercetin delivery: A comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE)*. *LWT - Food Science and Technology*, 2014. **59**(1): p. 115-121.
137. Garg, N.K., et al., *Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics*. *Colloids Surf B Biointerfaces*, 2016. **146**: p. 114-126.
138. Ayyanaar, S., et al., *ROS-Responsive Chitosan Coated Magnetic Iron Oxide Nanoparticles as Potential Vehicles for Targeted Drug Delivery in Cancer Therapy*. *Int J Nanomedicine*, 2020. **15**: p. 3333-3346.
139. Wang, T., et al., *Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44*. *J Nanobiotechnology*, 2017. **15**(7): p. 1-12.
140. Kumari, M., et al., *PGMD/curcumin nanoparticles for the treatment of breast cancer*. *Sci Rep*, 2021. **11**(1): p. 1-17.
141. Askar, M.A., et al., *Synergistic Effect of Quercetin Magnetite Nanoparticles and Targeted Radiotherapy in Treatment of Breast Cancer*. *Breast Cancer (Auckl)*, 2022. **16**: p. 1-17.
142. Yang, P., et al., *Doxorubicin and Edelfosine Combo-Loaded Lipid-Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma*. *Onco Targets Ther*, 2020. **13**: p. 8055-8067.
143. Novohradsky, V., et al., *Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells*. *Oncotarget*, 2018. **9**(47): p. 28456-28473.

144. Anjum, M.M., et al., *Development of Anacardic Acid/hydroxypropyl- β -cyclodextrin inclusion complex with enhanced solubility and antimicrobial activity*. Journal of Molecular Liquids, 2019. **296**: p. 1-10.
145. Cirri, M., et al., *Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy*. Drug Deliv, 2018. **25**(1): p. 1910-1921.
146. Carvalho, F.V., et al., *Docetaxel Loaded in Copaiba Oil-Nanostructured Lipid Carriers as a Promising DDS for Breast Cancer Treatment*. Molecules, 2022. **27**(24): p. 1-18.
147. Agrawal, A.K., et al., *"Liquid Crystalline Nanoparticles": Rationally Designed Vehicle To Improve Stability and Therapeutic Efficacy of Insulin Following Oral Administration*. Mol Pharm, 2017. **14**(6): p. 1874-1882.
148. Makoni, P.A., K.W. Kasongo, and R.B. Walker, *Preformulation studies of efavirenz with lipid excipients using thermal and spectroscopic techniques*. Pharmazie, 2020. **75**(9): p. 417-423.
149. Samy, A.M., et al., *Screening Study for Formulation Variables in Preparation and Characterization of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers*. Univers. J. Pharm. Res., 2020. **4**(6): p. 8-19.
150. Jain, S., et al., *Surface stabilized efavirenz nanoparticles for oral bioavailability enhancement*. J Biomed Nanotechnol, 2013. **9**(11): p. 1862-1874.
151. Oshiro-Junior, J.A., et al., *Phthalocyanine-loaded nanostructured lipid carriers functionalized with folic acid for photodynamic therapy*. Mater Sci Eng C Mater Biol Appl, 2020. **108**: p. 1-17.
152. Sabzichi, M., et al., *Vitamin D-Loaded Nanostructured Lipid Carrier (NLC): A New Strategy for Enhancing Efficacy of Doxorubicin in Breast Cancer Treatment*. Nutr Cancer, 2017. **69**(6): p. 840-848.
153. Agrawal, A.K., et al., *Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration*. Biomacromolecules, 2014. **15**(1): p. 350-360.
154. Singh, S., et al., *Insulin- and quercetin-loaded liquid crystalline nanoparticles: implications on oral bioavailability, antidiabetic and antioxidant efficacy*. Nanomedicine (Lond). 2018. **13**: p. 521-537.
155. Khan, S.A., et al., *Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS*. Pharmaceutics, 2020. **12**(11): p. 1-26.
156. Houacine, C., *Resveratrol Nanostructured Lipid Carrier for targeted delivery to breast cancer*, in *Pharmacy and Biomedical Sciences*. 2018, University of Central Lancashire: Central Lancashire. p. 339.
157. Aditya, N.P., et al., *Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostata cancer activity*. J Agric Food Chem, 2013. **61**(8): p. 1878-1883.
158. Pal, K., et al., *Folic acid conjugated curcumin loaded biopolymeric gum acacia microsphere for triple negative breast cancer therapy in invitro and invivo model*. Mater Sci Eng C Mater Biol Appl, 2019. **95**: p. 204-216.

159. An, X., et al., *Oxidative cell death in cancer: mechanisms and therapeutic opportunities*. Cell Death Dis, 2024. **15**(8): p. 1-20.
160. Liu, F., et al., *Baicalin-loaded folic acid-modified albumin nanoparticles (FA-BSANPs/BA) induce autophagy in MCF-7 cells via ROS-mediated p38 MAPK and Akt/mTOR pathway*. Cancer Nanotechnology, 2022. **13**(2): p. 1-21.
161. Mohammed Asik, R., et al., *Anticancer Potential of L-Histidine-Capped Silver Nanoparticles against Human Cervical Cancer Cells (SiHA)*. Nanomaterials (Basel), 2021. **11**(11): p. 1-17.
162. Arroyo-Crespo, J.J., et al., *Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression*. Int J Cancer, 2019. **145**(8): p. 2267-2281.
163. Bouchalova, P. and P. Bouchal, *Current methods for studying metastatic potential of tumor cells*. Cancer Cell Int, 2022. **22**(394): p. 1-22.
164. Qin, X., et al., *Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats*. Biochem Pharmacol, 2017. **143**: p. 129-139.
165. Kim, C.H., et al., *Sterically Stabilized RIPL Peptide-Conjugated Nanostructured Lipid Carriers: Characterization, Cellular Uptake, Cytotoxicity, and Biodistribution*. Pharmaceutics, 2018. **10**(4): p. 1-21.
166. Kushwah, V., et al., *Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management*. Acta Biomater, 2018. **73**: p. 424-436.
167. Kushwah, V., et al., *Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy*. Nanomedicine, 2018. **14**(5): p. 1629-1641.